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In order to metastasize, cancer cells must undergo phenotypic transition from an
anchorage-dependent form to a motile form via a process referred to as epithelial to mes-
enchymal transition. It is currently unclear whether metastatic cells emerge late during
tumor progression by successive accumulation of mutations, or whether they derive from
distinct cell populations already present during the early stages of tumorigenesis. Sim-
ilarly, the selective pressures that drive metastasis are poorly understood. Selection of
cancer cells with increased proliferative capacity and enhanced survival characteristics
may explain how some transformations promote a metastatic phenotype. However, it is
difﬁcult to explain how cancer cells that disseminate can emerge due to such selective
pressure, since these cells usually remain dormant for prolonged periods of time. In the
current study, we have used in silico modeling and simulation to investigate the hypoth-
esis that mesenchymal-like cancer cells evolve during the early stages of primary tumor
development, and that these cells exhibit survival and proliferative advantages within the
tumor microenvironment. In an agent-based tumor microenvironment model, cancer cell
agents with distinct sets of attributes governing nutrient consumption, proliferation, apop-
tosis, random motility, and cell adhesion were allowed to compete for space and nutrients.
These simulation data indicated that mesenchymal-like cancer cells displaying high motility
and low adhesion proliferate more rapidly and display a survival advantage over epithelial-
like cancer cells. Furthermore, the presence of mesenchymal-like cells within the primary
tumor inﬂuences the macroscopic properties, emergent morphology, and growth rate of
tumors.
Keywords: tumor microenvironment, epithelial to mesenchymal transition, agent-based modeling and simulation,
complex systems
INTRODUCTION
Cancer progression is typically described as a multi-step process
whereby normal replicating cells undergo a series of progressive
mutations that lead to dysregulated proliferation, local invasion,
and metastatic dissemination (Fidler and Kripke, 1977; Hana-
han and Weinberg, 2000). Metastasis was thought to depend on
cancer cells which emerge late in the course of disease progres-
sion. However, this view has recently been challenged by data
from gene expression proﬁling and reports that metastatic cells
disseminate early during primary tumor progression (Bacac and
Stamenkovic, 2008; Eyles et al., 2010). The factors that drive this
early dissemination are unclear.
The early acquisition of a metastatic phenotype is proba-
bly facilitated by epithelial to mesenchymal transition (EMT)
of cancer cells (Gavert and Ben-Ze’ev, 2010), a process which
normally occurs during embryogenesis (Kalluri and Weinberg,
2009). Several distinct changes in cell properties take place dur-
ing EMT, including reduced intercellular adhesion and increased
cell motility. A central feature of EMT is the down-modulation of
E-cadherin, a cell adhesion molecule (CAM) which binds epithe-
lial cells together through adherens junctions. Cells undergoing
EMT exhibit fewer adherens junctions, and can thus delaminate
from the normal epithelium (Strumane et al., 2004). Moreover,
by up-regulation of alternative adhesion molecules such as beta-
integrins,these cells can migrate toward and invade the basement
membrane. EMT-like processes are likely to drive the acquisition
ofametastaticphenotypebycancercells(Kalluri,2009;Gavertand
Ben-Ze’ev, 2010) and tumor-inﬁltrating immune cells have been
shown to favor these changes (Santisteban et al., 2009; Toh et al.,
2011; Bonde et al., 2012). But the factors which promote EMT
and drive dissemination of metastatic cells during early cancer
progression remain uncertain.
One possible approach to identifying these factors could be
to consider tumor growth from an evolutionary perspective;
although cancer cells in a tumor share the same clonal origin,
thesecellssubsequentlyexhibitgeneticandepigeneticheterogene-
ity (Gonzalez-Garcia et al., 2002; Maley et al., 2006; Merlo et al.,
2006). There is a constant selective pressure within the developing
tumor that favors cells with survival and proliferative advantages
(Merlo et al.,2006;Polyak et al.,2009). This selection process may
drive cancer cells toward the acquisition of genotypes and phe-
notypes that allow the tumor to expand. However, it is currently
unclear how these genotypes and phenotypes lead to the devel-
opment of metastatic cells, since metastatic lesions may outgrow
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manyyearsafterthecancercellsinitiallydisseminate.Characteris-
ticsofcancercellswhichareadvantageousfortheirsurvivalonlyin
the long term cannot account for their selection in the early stages
ofcancer.Wethereforehypothesizedthatamesenchymal-likephe-
notype might also confer a selective advantage on cancer cells in
the early stages of primary tumor development. This hypothesis
is however difﬁcult to test using conventional in vivo or in vitro
experiments.
Inrecentyears,fusionof computationalandbiologicalsciences
has led to signiﬁcant advances in our understanding of biologi-
cal systems (Brent and Bruck, 2006). Computational approaches
havepermittedthedevelopmentof relevantinsilico modelswhich
support the analysis of complex biological systems (Kohl et al.,
2000; Noble, 2008). We therefore sought to determine whether a
computational model could be used to identify the early selection
advantage conferred by a mesenchymal-like phenotype among
primary tumor cells. The growth of a tumor involves complex
interactions between cancer cells and their surrounding microen-
vironment through cell signaling, adhesive forces, and competi-
tion for nutrients. Recently, agent-based approaches have proved
to be an effective tool for modeling complex biological systems
(Bonabeau, 2002; Grimm and Railsback, 2005). An agent-based
model(ABM)simulatestheactionsandinteractionsof individual
entities or agents in order to assess their effects on the system as
a whole. Using a set of simple, well-deﬁned rules governing each
individual agent on the micro-scale, the emergence of complex
patterns at the macro-scale can be successfully simulated.ABM of
thetumormicroenvironmenthavealreadybeenusedintherecent
pasttostudyhowatumoremergesasaconsequenceofinteractions
between individual cancer cells and their environment (Rejniak
and Anderson, 2010).
Here we have used an in silico ABM of tumor to investigate
whether mesenchymal-like cancer cells are preferentially selected
in an avascular primary tumor. Initial simulations were per-
formed using a homogeneous cell population to determine how
the physiological properties of cancer cells (including prolifer-
ation and apoptosis rates, random motility, cell–cell adhesion,
cell–extracellularmatrix(ECM)adhesion)andtheirnutrientcon-
sumptioninﬂuencethemorphologyandgrowthoftumors.Subse-
quentsimulationswereperformedusingheterogeneoustumorcell
populations to determine how distinct clones of cancer cells com-
pete in a growing tumor.We show that the subpopulation favored
by the selection process within the primary tumor also presents
metastatic properties,providing a potential explanation as to why
metastasis can be selected at an early stage of tumorigenesis.
MATERIALS AND METHODS
The model represents a two-dimensional approximation of avas-
cular tumor growth which consists of tumor cells,an ECM region
wherethetumorcellsgrow,andthenutrientswhichsupportthese
cells. The ECM is a geometric square 2mm×2mm in size.
Two types of nutrients ﬂow through the ECM, one of which
supports cell proliferation, and the other which supports cell sur-
vival. Nutrient concentration is deﬁned over a regular 200×200
grid.Thegridspacing,orlatticeconstant,isΔ=10μm.Nutrients
diffusetowardthecenterof theECMfromhypotheticalbloodves-
sels located at top and bottom of the grid,where they have a ﬁxed
concentration. The governing equation is derived from Ferreira
et al. (2002):
∂ni (  x,t)
∂t
= Di∇2ni (  x,t) − λiγini (  x,t)T (  x,t), (1)
where n(  x,t) is nutrient concentration ﬁeld over positions   x =
(x,y) on the lattice and time t,the subscript i refers to the type of
nutrient (i =1 for proliferation nutrient, i =2 for survival nutri-
ent), D is nutrient diffusion rate, T is the number of tumor cells
near the lattice node   x at time t, γ is the rate of consumption
of nutrient by normal cells, and λ is the factor denoting excess
nutrient consumption by tumor cells. Boundary conditions are
imposed as constant nutrient concentration at top and bottom:
∀x,tn i
 
x,top,t
 
= ni (x,bottom,t) = n0, (2)
andsemi-inﬁniteboundaryconditionsareimposedattheleftand
right boundaries. The diffusion equation is numerically solved
at every point (x, y) on the lattice using a ﬁnite difference
discretization (Kumar, 2001).
Tumorcellsaremobileagentswithacirculargeometryofdiam-
eter10μm.T umorcellagentsarefreetomoveinanydirectionover
the ECM. The physiological properties of tumor cells which are
modeled include their proliferation and apoptosis rates, nutrient
consumption rate, random cell motility, cell–cell adhesion, and
cell–ECM adhesion. Correspondingly, the state of a tumor cell
agentisdeﬁnedbyitssubpopulationtype(aninteger,s ∈{1,2,...,
S}), mass (m), position (  x), velocity (  v), cell cycle state, nutrient
consumption rate (λ), coefﬁcient of random motility (ξ), coefﬁ-
cient of adhesion with ECM as a friction coefﬁcient (μ; friction is
encountered as the cell moves over the ECM), and coefﬁcients of
adhesion with cells of various subpopulations (εss
  where s  ∈{1,
2,...,S}).Tumorcellsbelongingtodifferentsubpopulationshave
differentsetsofvaluesforeachoftheseparameters.Cellmovement
isdeterminedbytheforcesactingonacell.TherandomBrownian
motionofacellisincorporatedintheformofaLangevinequation:
m
d  v
dt
=− μ  v +   Frandom +   Fdeterministic, (3)
where   Frandom is a random stochastic force and   Fdeterministic rep-
resents deterministic forces. Each cell’s position   x at a particular
timet iscomputedusingthevelocityVerletalgorithmofmolecular
dynamics (Haile, 1992):
  x (t + Δt) =  x (t) +  v (t)Δt +
1
2
  a (t)Δt2, (4a)
  v (t + Δt) =  v (t) +
1
2
(  a (t) +  a (t + Δt))Δt, (4b)
where   v (t) and   a (t) are respectively the cell velocity and accel-
eration. In order to obtain accurate simulation results, the time
step Δt is taken as a very small value 0.001 in non-dimensional
units, where non-dimensionalization is with respect to the cell
time constant Δ2/ξ.
The random stochastic force on a cell is calibrated using exper-
imental observations of a cell’s random walk. Variance of   Frandom
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Table 1 | Simulation parameters.
Symbol Description Value Reference
d Cell diameter 1.0×10−5 m Toh et al. (2011)
τ Cell cycle time 28h Toh et al. (2011)
Δ Lattice constant 5.0×10−6 m Present study, comparable with Mallet and Pillis (2006)
L Number of grid elements 400 Present study, comparable with Mallet and Pillis (2006)
γ Nutrient consumption for a healthy cell 1.0×10−18 mol/s Casciari et al. (1992)
λ Excess consumption by a tumor cell 1–100 Ferreira et al. (2002), Mallet and Pillis (2006)
D Nutrient diffusion constant 1.0×10−9 m2/s Jeon et al. (2010)
n0 Nutrient concentration at boundary 0.1mol/m2 Jeon et al. (2010)
θ1 Proliferation parameter 0.3 Ferreira et al. (2002), Mallet and Pillis (2006)
θ2 Apoptosis parameter 0.03 Ferreira et al. (2002), Mallet and Pillis (2006)
α1 Proliferation rate 0.02–0.5 Ferreira et al. (2002), Mallet and Pillis (2006)
α2 Apoptosis rate 0.002–0.05 Ferreira et al. (2002), Mallet and Pillis (2006)
ε Strength of adhesion force 1–10 Jeon et al. (2010)
ζ Random cell diffusion coefﬁcient 2.0×10−14 m2/s Toh et al. (2011)
ξ Random cell motility 1–5 Present study
μ Cell–ECM friction coefﬁcient 0–0.5 Present study, comparable with Jeon et al. (2010)
σB Binding energy of a single bond 1.03×10−4 J/m2 Drasdo and Hoehme (2005)
E Young’s modulus 800Pa Drasdo and Hoehme (2005)
ν Poisson ratio 0.4 Drasdo and Hoehme (2005)
is speciﬁed by a parameter ς (in Table 1) and can be adjusted in
the model by multiplicative factor ξ representing a cell’s random
motility:
 
  Frandom (t)
 
= 0, (5a)
 
  Frandom (t)   Frandom
 
t   
= ξςδ
 
t − t  
. (5b)
  Fdeterministic represents deterministic forces, which in the
present study is intercellular adhesion/repulsion force. These
forces describe short range interactions between cells over a dis-
tance of one to two cell diameters due to physical contact between
their lamellipodia and ﬁlopodia protrusions. The attractive com-
ponent due to formation of bonds via CAMs is described as a sine
force:
Fadh = εss  sin
 
π(de − r)
2(de − d)
 
for d < r < de, (6)
where r is the distance between cell centers, d is cell diameter, de
is the outer diameter of a cell inclusive of lamellipodia and ﬁlopo-
dia extensions, and εss
  is the parameter representing strength of
intercellular adhesion between cells belonging to subpopulations
s and s . The repulsive component due to elastic deformation
upon contact or collision between cells is described using the JKR
model (Drasdo and Hoehme, 2005). The pull-off force, Fpulloff,i s
computed by solving the implicit equations:
δ =
1
2
(d1 + d2) − r =
2a2
˜ d
−
 
2πσBa
E
 
2
 
1 − ν2  (7)
a3 =
3˜ d
4E
  
1 − ν2 
 
Fpulloff +
3π
2
σB˜ d
+
 
3πσB˜ dFpulloff +
 
3π
2
σB˜ d
 2
⎤
⎦ (8)
where d1 and d2 are the cell diameters, δ denotes the central dis-
placement which measures the deformation of spheres along the
axis that joins their centers, ˜ d = d1d2
 
(d1 + d2), E is the Young’s
modulus of spheres, ν is the Poisson ratio, and σB is the bind-
ing energy of a single bond times the density of surface adhesion
molecules in the contact zone. The term a is called the contact
radius.
Cellsproliferateorundergo apoptosisdependingonthelocally
available nutrient concentration. A cell undergoes mitosis after
reachinganageτ(cellcycletime)withaprobabilityPprolif if there
is available space for the daughter cell (Ferreira et al.,2002):
Pprolif = α1
 
1 − exp
 
−
 
n1
 
θ1
 2  
, (9a)
where n1 is the amount of proliferation nutrient near the cell
and θ1 is the proliferation parameter. The factor α1 is adjusted to
achieve a desired overall proliferation rate, such as about 2% per
d a ya sr e p o r t e di nMehrara et al. (2009). A tumor cell undergoes
apoptosis with a probability Papoptosis when there is insufﬁcient
survival nutrient in the vicinity (Ferreira et al.,2002):
Papoptosis = α2 exp
 
−
 
n2
 
θ2
 2 
, (9b)
where n2 is the amount of survival nutrient near the cell and θ2
is the apoptosis parameter. The factor α2 is adjusted to achieve
an overall apoptosis rate of about 1/10th of the proliferation rate.
Apoptotic cells are immediately removed from the system.
Nutrientdiffusionandcelldynamicsequationsaresolveditera-
tively.Thedynamicsofnutrientsandcellsarecoupledinthemodel
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since nutrient concentration is inﬂuenced by consumption, and
cells proliferate, sustain, or undergo apoptosis depending upon
locally available nutrient concentration. However, since nutrient
ﬁelds diffuse much faster compared to the motion of cells, the
time step for computing nutrients is much smaller compared to
that for computing cell dynamics. This allows uncoupling where
cell dynamics and nutrient diffusion equations can be solved
alternately.
Tumor growth is simulated beginning with a single tumor cell.
NutrientconcentrationsareinitiallyuniformovertheentireECM,
equal to the concentration value at the blood vessels situated at
top and bottom of the ECM. As the simulation progresses, the
following observations are obtained from the model: (i) numbers
of cells of various population types, (ii) snapshots or images of
tumor morphology, (iii) nutrient concentrations over the ECM.
These observations are collected at regular intervals during simu-
lated tumor growth. Tumor morphology is a qualitative attribute
which was classiﬁed into one of three distinct categories based
on visual evaluation – compact morphology (where tumor cells
adheretogetherformingasinglemass),multinodularmorphology
(where tumor cells form more than one solid mass), and diffuse
morphologies (where tumor cells spread and are unable to form
a mass).
RESULTS
The model described in Section “Materials and Methods” was
used to simulate avascular tumor growth in vivo in two differ-
ent scenarios. In the ﬁrst instance, all cancer cell agents in the
tumor were identical and displayed the same phenotype, i.e., they
employed the same coefﬁcients of nutrient consumption, pro-
liferation, apoptosis, motility, cell–cell adhesion, and cell–ECM
adhesion. In the second case, the cancer cell agents were initially
of thesamephenotype,butafterthetumorhadgrowntoacertain
size,one of the cancer cells mutated toward a different phenotype.
If the mutated cell was able to survive and proliferate, the two
different cell lineages then grew in parallel within the same tumor
microenvironment. The simulation results are reported below.
INDIVIDUAL CELL CHARACTERISTICS DETERMINE TUMOR
MORPHOLOGY
Figures1and2showthegrowthratesandmorphologiesoftumors
thatemergefrominsilicosimulationsinwhichallcancercellagents
are identical. The properties of cancer cell agents are reﬂected in
the parameter values of their nutrient consumption rate (λ),ran-
domcellmotility(ξ),cell–celladhesionstrength(ε),andcell–ECM
adhesion strength (μ). These parameters were then varied in turn
across the simulations (only one parameter was altered at any
time while keeping the other variables constant in order to study
the contributions of individual cellular attributes).
Figure1showshowthegrowthrateandtheﬁnalsizeofatumor
changes as the nutrient consumption rate of cancer cell agents is
graduallyincreasedfrom1to40timesthatofanormalcell.Ascan-
cer cell agents consume more nutrients, the tumor changes from
an unrestricted growing mass (λ=1, 3) to one which reaches a
maximum size (λ≥5). This growth plateau is typical of avascular
tumors prior to angiogenic switch (the point at which the tumor
initiates angiogenesis to draw extra nutrients from the host).
FIGURE1|E f f e c to fnutrient consumption on tumor growth rate.The
ﬁgure shows typical growth curves obtained by varying nutrient
consumption rate λ. Increased nutrient consumption rates lead to smaller
tumors. For very low nutrient consumption rate, tumor growth does not
plateau.
Figure 2A shows the variation in tumor morphology with
alterednutrientconsumptionrateamongcancercells.Theamount
of nutrients available at a certain position is depicted by the
intensity of yellow shading, where shades close to black denote
nutrient depletion. It can be observed that nutrient is in plentiful
supply(noblackshades)whenconsumptionrateislow(λ=1,3).
However, nutrient is depleted in the vicinity of cancer cell agents
when the consumption rate is high (λ≥5). Few cells are able to
survive in regions of low nutrient availability. Accordingly,cancer
cell agents in our model were programmed to undergo apopto-
sis with a high probability when local nutrient supplies were no
longer sufﬁcient. As a result, both tumor size and frequency of
cancer cell agents depend on the rate of nutrient consumption by
the cancer cell agents. Tumor growth is arrested when nutrient is
depleted in regions surrounding the cancer cell agents, which can
be seen as dark patches in Figure 2A for consumption rate λ≥5.
Another factor which determines tumor size and morphology
is the mobility of cancer cell agents,which allows agent migration
to locations where more nutrients are available. The movement
of cancer cell agents in the system is determined by three factors:
their inherent random motility (ξ), cell–cell adhesion (ε), and
cell–ECM adhesion (μ). The effect of varying these parameters is
shown in Figures 2B–D. Random motility refers to the propen-
sity of cells to move over the ECM, which is measured here in
nano-Newtons to represent Brownian motion of cells under the
inﬂuence of a stochastic force. As seen in Figure 2B, if cancer
cell agents are less motile (ξ=1, 5, 10nN), they tend to aggre-
gate, resulting in compact tumor morphology with or without
hollow core. However, when cell motility increases, the tumor
can either grow as a multinodular structure (ξ=20, 30, 40nN;
Figure 2B) or can form diffuse clusters of cells (see below). The
random motility of cancer cell agents can however be restricted
by cell–cell and cell–ECM adhesion. Figure2C shows the effect of
increasingcell–celladhesioninacasewherecancercellagentshave
high motility (ξ=20nN) and would thus tend to migrate away
(ε=1nN).Withthesemotilecellagents,increasingthestrengthof
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FIGURE 2 | Morphology of the emergent tumor is a function of the
properties of simulated cancer cell agents. (A)Tumor size is limited by
λ, the rate of nutrient consumption by cancer cells (shown as small red
circles). Nutrient concentration in a region is indicated by the shade of
yellow color, with black indicating zero concentration. (B)Tumor
morphology transitions from compact to multinodular upon increasing
random motility of cells ξ. (C,D) Increasing cell–cell adhesion ε, and/or
cell–ECM adhesion μ, restricts the mobility of cells, and leads to a
transition from a diffuse to a multinodular and ﬁnally to a compact
morphology.
cell–celladhesionleadstoatransitionintumormorphologyfrom
diffuse cluster (ε=1nN) to a multinodular tumor (ε=2, 4nN)
and ﬁnally to a compact tumor (ε=8, 16, 32nN). As shown in
Figure2D,a similar tendency to change tumor morphology from
a diffuse cluster to multinodular and then to a compact tumor
is observed upon increasing cell–ECM adhesion or friction from
very weak (μ=0.01) to strong adhesion (μ=0.8).
Taken together,these simulation data show that multiple para-
meters, including nutrient consumption rate, access to nutri-
ents,intrinsic motility,cell–cell adhesion,and cell–ECM adhesion
inﬂuence tumor growth and morphology.
INTERPLAY BETWEEN INDIVIDUAL CELL CHARACTERISTICS FOR
MULTINODULAR GROWTH
In order to understand the interplay between random cell motil-
ity, cell–cell adhesion, and cell–ECM adhesion, extensive simula-
tions were performed scanning a wide range of parameter space.
Figure3showsobservedtumormorphologyagainstvariouspara-
meter values. Diffuse and multinodular tumors were observed
only under conditions of low cell–ECM adhesion or friction
(μ=0.01, 0.1, and 0.2), whereas at higher values of cell–ECM
adhesion (μ≥0.4) tumor morphology was compact. For a ﬁxed
value of random motility and cell–cell adhesion, the morphology
maygraduallytransitionfromdiffuse,tomultinodular,andﬁnally
to compact as cell–ECM adhesion increases. For example, where
random motility is ξ=10nN and cell–cell adhesion is ε=1nN,
tumor morphology changes from diffuse, to multinodular, and
then to compact as cell–ECM adhesion increases from μ=0.01
to 0.2.
Similarly,foraﬁxedvalueofcell–ECMadhesionμ,tumormor-
phology may gradually transition from diffuse, to multinodular,
andthentocompactascell–celladhesionεincreases,orasrandom
cell motility ξ decreases. Where cell–ECM adhesion is μ=0.1
and cell–cell adhesion is ε=1nN, tumor morphology changes
from diffuse, to multinodular, and then to compact as random
motility decreases from ξ=20 to 1nN. When random motility
is ﬁxed at ξ=20nN, tumor morphology changes from diffuse,
to multinodular, to compact as cell–cell adhesion increases from
ε=1t o8n N .
In conclusion, there is a transition in simulated tumor mor-
phology as parameters representing cancer cell properties are
varied.Moreover,whilecompactgrowthcanbeobservedformany
different values of μ (cell–ECM adhesion) and ε (cell–cell adhe-
sion), multinodular tumors arise only when cancer cell agents
exhibit low to moderate cell–cell and cell–ECM adhesion.
GROWTH RATES OF TUMORS WITH HOMOGENOUS CELL POPULATIONS
We next compared the growth rates of multinodular and com-
pact tumors to determine whether either of these distinct mor-
phologies was favored by selective pressure. Figure 4 shows the
growthratesof tumorsforthesetof simulationsinwhichμ=0.1,
ξ=20nN,andcell–celladhesionεvariesbetween2and32nN.As
described above, under these conditions, simulated tumor mor-
phology changes from multinodular to compact as cell–cell adhe-
sion increases. Figure 4 shows that tumor growth is exponential
at early time points but quickly starts to plateau for both com-
pact and multinodular morphologies. While compact morphol-
ogy imposed a maximum growth limit on developing tumors,
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FIGURE 3 |Transition of tumor morphology from diffuse to multinodular
to compact.The ﬁgure shows change in morphology upon varying the
properties of cancer cells, including random cell motility ξ, cell–cell adhesion
ε, and cell–ECM adhesion (friction) μ. Cells with high motility and low cell–cell
and cell–ECM adhesion result in a diffuse or multinodular tumor, whereas
cells with low motility and high cell–cell and cell–ECM adhesion result in a
compact tumor. In all of these simulations the rate of nutrient consumption λ
is equal to 10.
FIGURE 4 |The growth rate of a tumor depends on the properties of
cancer cells and on tumor morphology. Initially all tumors grow
exponentially and with time their growth plateaus. However, multinodular
tumors can initiate new phases of growth at a linear rate.
T a b l e2|P a r ameter values for epithelial-like and mesenchymal-like
cancer cells in simulations of tumor growth with heterogeneous cell
populations.
Label Cell type Random
motility (nN)
Cell–cell
adhesion (nN)
Cell–ECM
adhesion
E1 Epithelial-like 1 2 0.1
E2 Epithelial-like 1 4 0.2
E3 Epithelial-like 10 4 0.2
E4 Epithelial-like 1 2 0.4
E5 Epithelial-like 10 4 0.4
M1 Mesenchymal-like 5 4 0.01
M2 Mesenchymal-like 20 4 0.1
M3 Mesenchymal-like 30 2 0.2
M4 Mesenchymal-like 40 4 0.2
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FIGURE 5 | Competition between epithelial-like and
mesenchymal-like cells in a growing avascular tumor.Tumor growth
initially begins as a homogenous mass of epithelial-like cells with low
motility and high adhesion. When the tumor includes 50 cells, one of
the cells randomly mutates into a mesenchymal-like cell with high
motility and low adhesion.The mesenchymal cell generates its own
lineage and competes with epithelial-like cells in the tumor
microenvironment.Though all cells have the same proliferation and
apoptosis rates, mesenchymal-like cells dominate the tumor due to
their greater mobility. Five types of epithelial-like cells (E1–E5) and four
types of mesenchymal-like cells (M1–M4) were paired in 20 different
simulations (Table 2).
multinodular tumors were able to overcome this growth plateau
and continued linear increases in size.
These observations may be interpreted as follows; initially all
cancer cell agents have free access to space and nutrients,hence all
cancercellsareabletoproliferateandtumorgrowthisexponential.
As the tumor grows larger,cell agents within the tumor proliferate
more slowly due to restricted space and limited nutrients, thus
tumor growth begins to plateau. The maximum size of a tumor is
subsequently reached when nutrient consumption by cell agents
exceeds the incoming supply from local blood vessels. Whereas
a compact tumor is forced to stop growing at this stage, the low
adhesion/high motility agents within multinodular tumors can
migrateoutof thestagnatednoduletoaccessadditionalspaceand
nutrients. Cells leaving a nodule can then proliferate to form new
satellite nodules, allowing a multinodular tumor to grow in an
unrestricted fashion.
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These results indicate that tumor growth rate is intricately
linkedwithtumormorphology.Whilecompacttumorseventually
reach a growth plateau, multinodular tumor growth slows when
nutrientsarelimitingbutdoesnotplateau.Thesedatasuggestthat
cancercellswhichformamultinodulartumormayhaveaselective
advantage over those which grow as a compact tumor.
TUMOR GROWTH WITH HETEROGENEOUS CELL POPULATIONS
Tumorsaremadeupof heterogeneouscancercellpopulationsand
competingclones(GatenbyandGillies,2008).Basedontheresults
shown in Sections “Interplay Between Individual Cell Character-
istics for Multinodular Growth” and “Growth Rates of Tumors
with Homogenous Cell Populations,”we next modeled two types
of cancer cells: epithelial-like cancer cells with properties of low
motility and high adhesion (which form compact tumors), and
mesenchymal-like cancer cells with properties of high motility
and low adhesion (which form multinodular tumors). We then
tested whether mesenchymal-like cancer cells could outcompete
epithelial-like cancer cells in the tumor microenvironment.
Wemodeledgeneticinstabilityofcancercellsusingtheassump-
tion that tumor cells are initially identical and epithelial-like,
but 14days after tumor initiation, when the tumor consists of
50 cells, one of the cancer agents (selected randomly) mutates
to become mesenchymal-like. The time point of 14days corre-
sponds to the time where we observed cancer cell dissemination
in mouse model of spontaneous melanoma (Eyles et al., 2010).
After this isolated mutation event, there are no further mutations
and tumor growth is allowed to continue normally. The mutant
mesenchymal-likecellmustinitiallycompeteagainst49epithelial-
like cells and undergo clonal expansion to generate additional
mesenchymal-likecellstopopulatethetumormicroenvironment.
Simulations were performed with ﬁve different types of
epithelial-like cells (labeled E1 to E5) and four different types
of mesenchymal-like cells (labeled M1 to M4). The parameter
values describing their random motility, cell–cell adhesion, and
cell–ECM adhesion are shown in Table 2. The strength of cell–
cell adhesion between cells of different types is 1nN. Figure 5
shows the growth rates of epithelial-like (red) and mesenchymal-
like (blue) populations. In the majority of the simulations, it can
be seen that the mesenchymal-like population becomes dominant
within a few hundred hours after the mutation event.
Figure 6 shows the morphologies of simulated tumors cor-
responding to the cases shown in Figure 5. Epithelial-like cells
(red) and mesenchymal-like cells (blue) are shown. The Figure
indicates that epithelial-like cells and mesenchymal-like cells typ-
ically grow side-by-side as two separate clumps of cells. Note that
although the epithelial-like and the mesenchymal-like cells have
identical proliferation and apoptosis rates in these simulations,
the mesenchymal-like cells are able to grow more rapidly due to
their higher mobility, which provides access to more space and
additional nutrients to support expansion. In addition, careful
examination indicates that in many instances, mesenchymal-like
cellssurroundtheepithelialcellsandeffectivelystarvetheseclones
of space and nutrients to slow their growth.
Similar results were obtained when mesenchymal transition
was allowed at 65days after tumor initiation (1 mesenchymal for
200 epithelial cells). These simulation data indicate that even a
FIGURE 6 | Morphologies resulting from simulated competition
between epithelial-like cells and mesenchymal-like cells in a growing
avascular tumor.The tumors correspond to the same 20 simulations
shown in Figure 5, with ﬁve kinds of epithelial-like cells (E1–E5) and four
kinds of mesenchymal-like cells (M1–M4) paired together. Epithelial-like
(red) and mesenchymal-like (blue) cells usually grow as separate lumps.
However, mesenchymal cells are more mobile and often surround the
epithelial cells to starve them of space and nutrients, further slowing the
growth of epithelial-like cells.
single mesenchymal-like cancer cell mutant can survive in the
early tumor and will eventually come to dominate the entire
tumor cell population. Mesenchymal-like cancer cells thus have
greater proliferative potential and survival characteristics in the
developingtumorandmaythereforeexhibitaselectionadvantage
over competing epithelial-like cancer cells.
DISCUSSION
In the current report, we used an in silico model to demonstrate
that cancer cells with a mesenchymal-like phenotype (low adhe-
sion, high motility) have a survival and proliferative advantage in
the microenvironment of an avascular tumor (Figure 7).
Our model shows that tumor morphology is determined by
the properties of individual cancer cells and by nutrient distri-
bution. Conversely, tumor morphology may provide informa-
tion on individual cancer cells and the prevailing growth con-
ditions within that tumor. Multinodular morphology is favored
by high random cell motility and low cell–cell and cell–ECM
adhesion,whichareattributesofmesenchymalcells,whereascom-
pact tumor morphology is favored by low random cell motility
and high cell adhesion, which are characteristics of epithelial
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FIGURE 7 | Selection of metastatic cancer cells.Tumor-inﬁltrating
macrophages (TAM) and granulocytic myeloid-derived suppressor cells
(G-MDSC) promote epithelial-mesenchymal transition (EMT) of cancer cells.
Mesenchymal cancer cells (low adhesion and high motility) give rise to rapidly
growing tumors with multinodular morphology.This growth advantage
explains the superior aggressiveness of multinodular tumors. It also predicts
that, under conditions of limited access to nutrients, cancer cells with strong
metastatic propensity will be selected.
cells. Competition for nutrients is also necessary for the emer-
gence of multinodular tumor morphology. This ﬁnding is in
agreement with evidence from the literature showing that mes-
enchymal transition and nutrient depletion are linked to multin-
odular tumor formation and metastasis: for example, increased
risk of metastasis has been associated with multinodular tumors
(Fasani et al., 1999). Furthermore, in hepatocellular carcinoma
(HCC) it has been observed that hypoxia induced by treatment
with tumor necrosis factor-α-converting enzyme stimulates the
growth of HCC cells and promotes tumor multinodularity and
metastasis (Song et al., 2001). Similarly, increased numbers of
tumor nodules and accelerated metastasis were observed in mice
treated with drugs that inhibit tumor angiogenesis (Ebos et al.,
2009; Paez-Ribes et al., 2009). Our model explains that antian-
giogenic treatments, which aim at starving tumors, favor the
emergence of more aggressive variants with increased propensity
to metastasize.
The ﬁtness of epithelial-like and mesenchymal-like cancer cells
was compared using two types of in silico simulation. Firstly, we
showed that multinodular tumors have a proliferative and sur-
vival advantage over compact tumors. The growth of compact
tumors reaches a plateau dues to nutrient depletion, whereas
multinodular continue to grow. The reason behind this is that
mesenchymal-like cancer cells can escape out of individual nod-
ules which have stopped growing and gain access to nutrients
in neighboring regions, supporting the formation of new nod-
ules.Themesenchymal-likecancercellswhichformmultinodular
tumors therefore appear to exhibit greater ﬁtness (i.e., ability to
survive and proliferate) when compared with the epithelial-like
cancer cells which form compact tumors. Secondly, in simulation
experiments where epithelial and mesenchymal populations of
cancer cells were allowed to compete in the same tumor microen-
vironment, we found that mesenchymal-like cancer cells usu-
ally came to dominate the tumor. Thus, if it is possible for a
mesenchymal-like cancer cell to emerge in a tumor as a conse-
quence of a single mutation event, then it may be possible for
that cell to proliferate and establish a new dominant lineage. This
wouldsuggestthatEMT,whichislinkedtometastaticprogression
(Kalluri,2009;GavertandBen-Ze’ev,2010)mightbefavoredearly
during the development of avascular primary tumors. It would
explain recent studies showing that cancer cell dissemination is
an early event in tumor development (Husemann et al., 2008;
Eyles et al.,2010). Importantly,it may also explain the paradox of
metastatic cell selection despite prolonged metastatic dormancy.
Our simulations show that cancer cells with metastatic poten-
tial are selected because they have a growth advantage within the
primary tumor.
Thegreaterabilityof mesenchymal-likecancercellstoprolifer-
ateandsurviveisconsistentwiththeobservedassociationbetween
primary tumor size and increased risk of metastasis which under-
lies the TNM staging system (Duffey et al., 2004; Giordano et al.,
2004). Since mesenchymal-like cells are linked to both metasta-
sis and multinodular tumors, which can grow in an unrestricted
fashion,apositivecorrelationbetweentumorsizeandmetastasisis
predictable, despite the observation that dissemination is an early
event.
In summary, the ﬁndings reported here using in silico sim-
ulations provide potential explanations for the propensity of
multinodular tumors to undergo metastasis, and may clarify how
metastatic cells could emerge early in an avascular tumor. Each of
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the above individual observations is consistent with the concept
that EMT confers a selective advantage on cancer cells in a tumor
with restricted access to nutrients.
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